Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,323 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Anomalies Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms

NCT04661215
View directory record Official record
Conditions
Gastroparesis, Idiopathic Gastric Motility Disorder, Diabetic Gastroparesis
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
5
States / cities
Scottsdale, Arizona • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 16, 2026, 5:32 AM EDT
Completed No phase listed Observational

Screening in Oculopharyngeal Muscular Dystrophy

NCT02877784
View directory record Official record
Conditions
Oculopharyngeal Muscular Dystrophy
Interventions
Videofluoroscopic swallowing study, Functional Oral Intake Scale, Eating Assessment Tool-10
Procedure · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 16, 2026, 5:32 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

NCT05883748
View directory record Official record
Conditions
Erythropoietic Protoporphyria
Interventions
DISC-1459
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
12 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 16, 2026, 5:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration

NCT00587535
View directory record Official record
Conditions
Hemochromatosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 16, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention

NCT04923880
View directory record Official record
Conditions
Cystic Fibrosis, Quality of Life
Interventions
Implementation of Primary Palliative Care Intervention in CF Centers
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 16, 2026, 5:32 AM EDT
Active, not recruiting Phase 3 Interventional

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

NCT06255782
View directory record Official record
Conditions
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn
Interventions
ECUR-506
Genetic
Lead sponsor
iECURE, Inc.
Industry
Eligibility
24 Hours to 7 Months · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 16, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

NCT00645788
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ciprofloxacin (Cipro Inhale, BAYQ3939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
58
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 16, 2026, 5:32 AM EDT
Recruiting No phase listed Observational

PiMZ Longitudinal Cohort (PiMZ Logic)

NCT06505603
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema or COPD
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 16, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

NCT03525574
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
52
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 16, 2026, 5:32 AM EDT
Withdrawn Not applicable Interventional

The Relationship Between CFTR Gene Mutations and Exercise Capacity

NCT05157646
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Fitness tracker
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 16, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men

NCT04186260
View directory record Official record
Conditions
NAFLD
Interventions
NAFLD-specific weight loss intervention, Wait-list control
Behavioral · Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 16, 2026, 5:32 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

A Social Media Approach to Improve Genetic Risk Communication Phase I

NCT01645904
View directory record Official record
Conditions
Hereditary Diseases
Interventions
Audiotaped Focus Group, Demographic Questionnaire, Audiotaped Interview, WAMMI Inventory
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 16, 2026, 5:32 AM EDT
Not listed No phase listed Observational

Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders

NCT01438385
View directory record Official record
Conditions
Ampullary Cancer, Duodenal Cancer, Bile Duct Cancer, Bile Duct Disorders, Gallstones, Obstructive Jaundice, Pancreatic Disorders (Noncancerous), Colorectal Cancer, Esophageal Cancer, Barrett's Esophagus, Gastric Malignancies, Pancreatic Cancer, Pediatric Gastroenterology, Cholangiocarcinoma, Pancreatic Pseudocysts, Acute and Chronic Pancreatitis, Recurrent Pancreatitis, Cholangitis, Bile Leak, Biliary Strictures, Pancreatic Divisum, Biliary and Pancreatic Stones, Choledocholithiasis
Interventions
Interventional Endoscopy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 16, 2026, 5:32 AM EDT
Not listed Phase 2 Interventional

Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

NCT03831698
View directory record Official record
Conditions
Colorectal Cancer, Lynch Syndrome
Interventions
Omega-3 fatty acid ethyl esters (2 gram)
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Oct 16, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sweat Evaporimeter Measurement

NCT01708655
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sweat Evaporimeter measurement
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 16, 2026, 5:32 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

NCT06149793
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Interventions
Empagliflozin, Placebo Control
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 16, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional

Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

NCT00043316
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
interferon gamma-1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
12 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2007 · Synced Oct 16, 2026, 5:32 AM EDT
Completed No phase listed Observational

Evaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients

NCT04994301
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lung T1 MRI
Diagnostic Test
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
5 Years to 11 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 16, 2026, 5:32 AM EDT
Recruiting No phase listed Observational

A Prospective Database of Infants With Cholestasis

NCT00061828
View directory record Official record
Conditions
Biliary Atresia
Interventions
Not listed
Lead sponsor
Arbor Research Collaborative for Health
Other
Eligibility
Up to 6 Months
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2029
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 16, 2026, 5:32 AM EDT
Recruiting Not applicable Interventional

Velopharyngeal Dysfunction in Head & Neck Cancer Patients, Pilot Study

NCT07264036
View directory record Official record
Conditions
Velopharyngeal Insufficiency, Head and Neck Cancer, Survivorship, Dysphagia, Speech Disorder
Interventions
Pharyngeal Wall Augmentation Injection
Procedure
Lead sponsor
Vanessa Torrecillas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 16, 2026, 5:32 AM EDT
Recruiting Phase 3 Interventional

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

NCT05677971
View directory record Official record
Conditions
Alpha1-Antitrypsin Deficiency
Interventions
Fazirsiran Injection, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 16, 2026, 5:32 AM EDT
Completed No phase listed Observational Results available

The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment

NCT02763215
View directory record Official record
Conditions
Wilson Disease
Interventions
Standard of Care Medications
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
New Haven, Connecticut • Chicago, Illinois • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 16, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

NCT06350474
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase)
Other
Lead sponsor
Nicole Hamblett
Other
Eligibility
12 Years and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
81
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 16, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis

NCT01880723
View directory record Official record
Conditions
Cystic Fibrosis, Healthy
Interventions
Albuterol, Placebo saline
Drug
Lead sponsor
University of Arizona
Other
Eligibility
15 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 16, 2026, 5:32 AM EDT